GLP-1 Medications
60 articles on GLP-1 Medications, written by Shotlee and medically reviewed for clinical accuracy.
Beyond the Scale: Tracking GLP-1 Success with Advanced Health Monitoring
GLP-1 medications like Ozempic and Wegovy are transforming weight management, but understanding your body's response is key. Learn how innovative health monitors can help you track progress and manage side effects effectively.
7 min read
GLP-1 Weight Loss Drugs: Impact on Food Industry & Your Diet
New market data suggests a unique opportunity for protein-focused brands as GLP-1 therapies alter consumer eating habits. Learn how this shift affects your health strategy.
7 min read
Beyond 'Ozempic Teeth': Understanding and Managing 'Ozempic Breath'
The rise of GLP-1 medications like Ozempic and Mounjaro has brought about new conversations around their side effects, including the emerging concern of 'Ozempic breath.' This article delves into the causes, implications, and effective management strategies for this common issue.
7 min read
GLP-1 Weight Loss: What Happens When You Stop Semaglutide or Tirzepatide?
A comprehensive analysis of recent data shows that stopping GLP-1 medications like Ozempic and Wegovy often leads to weight regain and a return of cardiometabolic risk markers. Here is what you need to know about long-term outcomes and maintenance strategies.
7 min read
The Protein Revolution: How GLP-1s and Pulse Crops are Reshaping Agriculture and Nutrition
As GLP-1 medications like Ozempic and Wegovy change dietary habits, U.S. farmers are pivoting to pulse crops to meet the surging demand for high-protein foods.
2 min read
Aston Gynaecologist Investigates Ozempic, Mounjaro Impact on PCOS
A leading gynaecologist at Aston Medical School is probing whether GLP-1 drugs like Ozempic and Mounjaro could transform care for women with PCOS. With a £60,000 NHS grant, Dr Shagaf Bakour aims to evaluate their effects on metabolic health and fertility. This investigation highlights hope for better treatment pathways amid rising interest in these weight loss jabs.
5 min read
Duodenal Resurfacing May Prevent Weight Regain After Stopping Ozempic
New research presented at Digestive Disease Week 2026 suggests a minimally invasive 'gut reset' procedure could help patients maintain weight loss after discontinuing GLP-1 medications like Ozempic and Wegovy. The findings address a major challenge in obesity treatment: weight regain after stopping therapy.
7 min read
News Personalities' Before & After Ozempic, GLP-1 Weight Loss Pics
Ozempic and other GLP-1 medications are transforming figures in Hollywood and newsrooms alike, with before and after pics of personalities like Oprah Winfrey and Joy Behar showcasing undeniable weight loss. A 2024 study highlights their history since 1986, exploding in popularity post-Wegovy's 2021 FDA approval for weight loss. Spot the telltale Ozempic neck and hands that give away users.
5 min read
Luke Combs Rejects GLP-1 for Weight Loss: 'Not the Short Way'
Country music sensation Luke Combs is turning down GLP-1 medications for weight loss, opting for the hard road instead. In a candid New York Times interview, he shares fears about his appearance affecting his career and why 'that stuff scares me more than the benefits.' This stance highlights debates around quick fixes versus lifelong habits in weight management.
4 min read
Ozempic and GLP-1 Drugs: Heart Benefits and Personal Realities
Thirty million Americans—one in eight—are turning to GLP-1 drugs like Ozempic for weight management and more, with data showing a 20% reduced risk of heart attacks and strokes. But what happens when the weight doesn't budge, as in 10% of users? This personal story explores the hype, realities, and broader implications of these medications.
4 min read
Health Canada Warns Against Buying Peptides Online—CBC News Buys Them Easily
Health Canada recently warned Canadians not to buy or use unauthorized injectable peptide drugs amid reports of adverse reactions. Yet CBC News effortlessly purchased three such products online from different sellers. Experts highlight serious risks and contrast them with regulated GLP-1 medications like Ozempic and Wegovy.
5 min read
Amazon, Walmart's GLP-1 Land Grab Bigger Than Weight Loss
Amazon and Walmart are racing to dominate GLP-1 medications like Eli Lilly's new oral Foundayo, but their strategies extend far beyond filling prescriptions for weight loss. With same-day delivery, telehealth, and integrated services, they're building 'continuous care commerce' platforms. This shift promises ongoing patient support for long-term therapy success.
5 min read
Investors' Ozempic Mania Could Harm Health Priorities
Institutional investors have sidelined climate change in ESG priorities, favoring health tech fueled by Ozempic and GLP-1 drugs. A Berenberg Bank survey of 200 investors ranks health first as climate slips to fifth. Yet, climate change poses severe health threats from heatwaves to vector-borne diseases—why this mania could backfire.
4 min read
Ozempic Isn't a Magic Fix: Semaglutide Risks in India
Semaglutide injections like Ozempic have arrived in India at low prices, exciting millions with diabetes and rising obesity. But experts like Dr. Gagandeep Singh caution it's no magic fix—weight returns upon stopping, muscle loss is common, and misuse risks malnutrition. Understand the real story behind these GLP-1 weight loss injections.
6 min read
Indians Turn to Untested Chinese Weight-Loss Peptides
It starts with an Instagram reel from an influencer hyping potent weight-loss peptides. Soon, Indians dive into YouTube explainers, Reddit threads, and chat groups, ending with unapproved shipments from China. Hundreds rely on these cheaper alternatives to pricey Mounjaro and Ozempic amid GLP-1 plateaus.
4 min read
Heather Gay's Ozempic Weight Loss Journey: RHOSLC Star's Transformation
Real Housewives of Salt Lake City star Heather Gay has shared her Ozempic-assisted weight loss journey, crediting the GLP-1 injection for noticeable results after initial slow progress. Losing around 30 pounds amid social pressures from friends' transformations, she called it a 'long, overdue glow-up' thanks to modern medicine. Despite Ozempic face rumors, Gay remains open about her experience.
4 min read
Time for Guardrails on GLP-1 Compounding: Safety Risks Exposed
America faces a crisis in unregulated compounded GLP-1 drugs, with FDA reporting 1,150 adverse events including hospitalizations and deaths. Exploiting shortages of semaglutide and tirzepatide, compounders flood the market with untested products, misleading consumers. Now, with the SAFE Drugs Act and FDA crackdowns, it's time to restore safety standards.
4 min read
ROOT Brands® Fills GLP-1 Gap with CRUSH™ & SCULPT™ After Ozempic® & Wegovy®
As millions using GLP-1 medications like Ozempic® and Wegovy® face post-treatment challenges such as muscle loss and weight regain, ROOT Brands® introduces CRUSH™ and SCULPT™. This cellular-first protocol supports metabolic function and lean muscle preservation without pharmaceuticals. Backed by science, it targets the 'GLP-1 gap' for long-term body composition success.
5 min read
Entrepreneur Uses AI to Build $1B Telehealth Company on GLP-1 Drugs
Matthew Gallagher, a 41-year-old LA entrepreneur, turned $20,000 into a nearly $2 billion telehealth empire with AI alone. Medvi sells GLP-1 drugs like Ozempic at $300 versus $1,000 retail, serving 250,000 customers. But rapid growth sparks debates on legality and fake ads.
5 min read
Ozempic and Weight-Loss Drugs Create Hidden Waste Disaster
The boom in weight-loss drugs like Ozempic is fueling a hidden environmental crisis, with production generating up to 120 million pounds of toxic solvent waste annually. Traditional solid-phase peptide synthesis relies on hazardous chemicals, but a groundbreaking water-based approach could eliminate this issue. Researchers have demonstrated a cleaner method matching traditional yields.
4 min read
Hims & Hers Surges After RFK Jr. Pushes Peptide Access on Joe Rogan
Hims & Hers shares surged Monday after HHS Secretary Robert F. Kennedy Jr. expressed urgency on the Joe Rogan Experience to make 14 peptides more accessible. He highlighted FDA's review of the science behind these GLP-1 active ingredients for diabetes and weight loss. This could signal easing regulatory headwinds for telehealth providers like Hims.
5 min read
Mars CEO Poul Weihrauch Named Novo Nordisk Board Observer
Novo Nordisk, key supplier of GLP-1 drugs like Ozempic and Wegovy, has appointed Mars CEO Poul Weihrauch as a board observer. This move highlights the growing impact of weight-loss medications on food consumption habits. As GLP-1 use rises, food giants are adapting to shifting snack demands.
5 min read
Gayle King Ozempic Rumors: 10-Year Weight Loss Photos Revisited
Gayle King has navigated a public weight loss rollercoaster over 10 years, mirroring Oprah's but without confirming GLP-1 meds like Ozempic. From Weight Watchers triumphs to soup fasts and Sports Illustrated swimsuit glory, her story highlights diet, exercise, and resilience. Speculation swirls around her recent gaunt look—Ozempic face or natural leanness?
5 min read
Mounjaro Maker Signs $2.7B AI Drug Research Deal
Eli Lilly, the maker of blockbuster GLP-1 drug Mounjaro, has signed a landmark $2.7 billion deal with AI drug discovery firm Insilico Medicine. This agreement builds on their 2023 software licensing pact and harnesses Insilico's AI engine to fast-track novel therapeutics across multiple areas. Patients and investors are watching closely for impacts on metabolic health innovations.
5 min read
PPH ETF: Drug Pricing Policy & Eli Lilly Risks in 2026
The VanEck Pharmaceutical ETF (PPH) offers broad pharma exposure but faces headwinds from U.S. drug pricing reforms and heavy Eli Lilly weighting. Down 8% in the past month despite 15% one-year gains, PPH's diversification is tested. Key risks include MFN pricing deals and GLP-1 competition.
5 min read
Peptide Gold Rush: Deregulation Set to Supercharge Shadow Industry
Peptides, once a Silicon Valley biohacking secret, are exploding in popularity—search interest now tops Ozempic. With RFK Jr. poised to reverse FDA restrictions, compounding pharmacies and telehealth platforms are racing to supply them legally. This could propel the $52B peptide market to $87B by 2035.
5 min read
Mars CEO Poul Weihrauch Named Novo Nordisk Board Observer
In a strategic move, Novo Nordisk has elected Poul Weihrauch, CEO of Mars, as a board observer to enhance its consumer presence in the competitive US obesity market. This comes alongside new board members and a 2025 leadership overhaul. The appointment underscores efforts to make Wegovy more accessible through telehealth and direct-to-consumer channels.
5 min read
Novo Nordisk's FDA-Approved GLP-1s Now on Hims & Hers
Hims & Hers Health, Inc. has partnered with Novo Nordisk to bring a broad assortment of FDA-approved GLP-1 medications to eligible customers, including the groundbreaking Wegovy® pill. This collaboration simplifies access with affordable prices, expanded doses, and diverse delivery methods. As the largest global consumer health platform for these approved meds, Hims & Hers is transforming weight management options.
4 min read
Boston Mayor Wu, Unions Limit GLP-1 Coverage for Weight Loss Drugs
Boston Mayor Michelle Wu announced a deal with unions to implement prior authorization for GLP-1 weight loss drugs like Ozempic and Wegovy, saving the city $10.6 million. This move addresses skyrocketing health costs that threatened 22.6% premium hikes. City workers must now get approval for coverage on these popular obesity treatments.
5 min read
India Steps Up Oversight on GLP-1 Drugs Over Improper Practices
India's drug regulator is cracking down on GLP-1 weight loss drugs due to improper sales and promotions. Inspections across 49 entities revealed violations, leading to notices and potential license cancellations. With semaglutide generics now available post-patent expiry, authorities emphasize prescription-only use by specialists.
4 min read
DCGI Intensifies Crackdown on Unauthorized GLP-1 Weight-Loss Drug Sales
India's DCGI is cracking down harder on the unauthorized sale of GLP-1 weight-loss drugs amid rising generic variants. Inspections at online pharmacies, wholesalers, and clinics aim to prevent misuse that could lead to serious health risks. Patients must seek prescriptions only from qualified endocrinologists or specialists.
4 min read
Ozempic Lightens Truckers' Loads: GLP-1 Cuts Food Freight
GLP-1 medications like Ozempic are reshaping America's waistlines—and its freight lanes. With 12% of U.S. adults adopting these appetite-suppressing drugs, food demand is down 3%, slashing millions of truckloads from snacks, beverages, and more. This public health trend is quietly disrupting the trucking industry.
6 min read
Is 'Ozempic Penis' Real? Experts Explain Weight Loss & Penis Size
The viral term 'Ozempic penis' suggests semaglutide increases size, but urologists clarify it's a visual illusion from fat loss. We explore the real, complex effects of GLP-1 medications on sexual health, from potential erection improvements to libido changes.
9 min read
Morning Squawk: Dow Streak, Fertilizer Prices, Novo Nordisk Wegovy & More
The latest Morning Squawk highlights the Dow's ongoing losing streak, climbing fertilizer prices, and Novo Nordisk's new Wegovy shot amid market volatility. President Trump ramps up criticism of Fed Chair Jerome Powell, urging continued investigation into the 'incompetent' leader. A judge's subpoena block adds tension to Trump's Fed nominee confirmation.
5 min read
Is Ozempic Behind Charles Barkley's Weight Loss? Slim Look Stuns in March Mad...
Charles Barkley's noticeably slimmer figure courtside during March Madness 2026 has sparked widespread speculation: Is Ozempic behind his weight loss? The NBA legend dropped nearly 90 pounds using GLP-1 drugs like Mounjaro and Zepbound, combined with diet and exercise. Fans are stunned, but Barkley credits hard work over hype.
5 min read
Melissa McCarthy Oscars Pics Spark Ozempic Face Rumors
Melissa McCarthy turned heads at the 2026 Oscars in a stunning gown, but her noticeably slimmer face reignited Ozempic rumors. Side-by-side pics with her 2012 Oscars appearance make the change crystal clear. Onstage, she even poked fun at the speculation during a Bridesmaids reunion.
4 min read
Novo Nordisk Expands Ozempic, Wegovy Testing on Adolescents
Novo Nordisk, maker of Ozempic and Wegovy, has launched a three-year research partnership to test weight-loss GLP-1 drugs on adolescents in Pacific Island nations, beginning in Fiji. Announced amid a Danish royal visit, this move addresses the obesity 'ticking bomb' threatening kids' lifespans. CEO Mike Doustdar urges bolder action on prevention and access.
5 min read
Kelly Osbourne to Demi Moore: 8 Stars' Weight Loss Sparks Ozempic Talks in 2026
Kelly Osbourne's black sequined mini dress at the BRIT Awards turned heads for more than fashion—her slimmer frame ignited Ozempic speculation. Joined by Demi Moore, Emma Stone, and others at 2026 red carpets, these stars' dramatic weight loss sparked debates on 'Ozempic face' and Hollywood beauty standards. Discover the details and medical context.
6 min read
How Drugs Like Ozempic Revolutionize Kidney Treatment
Chronic kidney disease affects over one in seven Americans, but new drugs like Ozempic are changing the game. GLP-1 receptor agonists, SGLT2 inhibitors, and finerenone offer additive benefits beyond traditional RAS inhibitors, potentially halting or reversing progression. Experts like Maarten Taal hail them as game-changers for kidney health.
5 min read
Study: Wegovy Vision Loss Risk 5x Higher Than Ozempic
A groundbreaking study reveals Wegovy carries a fivefold higher risk of vision-threatening ischemic optic neuropathy compared to Ozempic. Analyzing millions of FDA reports, researchers link the risk to semaglutide's higher doses in Wegovy. Amid rising lawsuits, patients need to weigh benefits against potential eye health dangers.
5 min read
Eli Lilly Invests $3B in China for Next-Gen Oral GLP-1 Drug Production
Eli Lilly is set to invest a substantial $3 billion in China over the next decade to bolster the production of its groundbreaking oral GLP-1 receptor agonist, Orforglipron. This strategic move aims to enhance supply chain capacity for a drug poised to treat type 2 diabetes and obesity.
8 min read
Fat Cells Burn Energy for Heat: Next Weight Loss Frontier
Fat tissue isn't just storage—it's a dynamic organ that can burn energy as heat, opening new doors for weight loss beyond appetite-suppressing drugs like Ozempic and Wegovy. Researchers are targeting brown and beige fat to boost calorie burn without triggering hunger. This could be the next era in metabolic therapies.
4 min read
Rachel Weisz in Vladimir Captures Midlife Libido Explosion from HRT & GLP-1s
Netflix's Vladimir stars Rachel Weisz as a 56-year-old consumed by desire, echoing a secret midlife libido explosion many women are experiencing. Attributed to surging HRT use and GLP-1 weight loss injections, this trend is reshaping confidence and relationships. From cultural hits to real-life chats, explore why midlife women feel hotter than ever.
4 min read
Meghan Trainor's 'Ozempic Face' in Side-by-Side Pics: Dramatic Changes
Meghan Trainor's striking transformation, showcased in side-by-side photos from 2014 and 2025, has ignited debates on 'Ozempic face' from GLP-1 drugs like Mounjaro. While her defined jawline looks stunning, experts note rapid fat loss can accelerate aging signs like sunken cheeks and wrinkles. Learn the facts amid body positivity backlash.
5 min read
GLP-1, Muscle Weakness & Obesity Care: Dr. Bob's Insights
As GLP-1 drugs like Ozempic revolutionize obesity and diabetes care, muscle weakness emerges as a key challenge. Dr. Bob reveals why 47-65% discontinue treatment, patient perceptions vs. reality, and proven strategies like protein intake and strength training. Explore the next frontier in preserving muscle for long-term health.
4 min read
Eli Lilly and Weight-Loss Pharma Now 20% of Irish Exports
Irish pharmaceutical exports hit a record €139bn in 2025, with GLP-1 weight-loss drugs from Eli Lilly and Novo Nordisk driving 20% of total goods exports. Eli Lilly's facilities in Ireland and massive US investments underscore the sector's growth. This boom promises faster access to innovative metabolic treatments for patients.
6 min read
FDA Issues Novo Untitled Letter for Apple-Inspired Ozempic Ad
Novo Nordisk has received a second FDA untitled letter in weeks, this time targeting an Ozempic digital ad that parodies Apple's 'Get a Mac' campaign with actors Justin Long and John Hodgman. The regulator cites misleading presentations of Ozempic's indications and unsubstantiated superiority claims over other GLP-1s. Understand the concerns and what it means for patients seeking accurate information on these therapies.
5 min read
RHOSLC Star Heather Gay's Face Transformed (Not Just Ozempic)
The Real Housewives of Salt Lake City star Heather Gay's face looks more voluminous at 49 than at 38, thanks to a series of cosmetic procedures—and a touch of Ozempic face. From Botox in her 30s to collagen stimulation now, her story highlights the blend of aesthetics and GLP-1 side effects. See how she navigated it all.
4 min read
How GLP-1s Helped a Rhode Island Mom Get Sober After Alcoholism
A Rhode Island mother battled alcoholism for years, losing custody of her son, until GLP-1 drugs like Wegovy and Mounjaro helped curb her cravings in a pilot program. Gina Roberts shares her journey to two years sober, her own apartment, and family reunion. Addiction specialist Dr. Steven Klein discusses the promising role of these medications alongside traditional supports.
6 min read
Donna Kelce Denies Weight-Loss Drugs, Credits Intermittent Fasting
Donna Kelce, mother of NFL stars Travis and Jason, is clapping back at online speculation that her slimmer figure on The Traitors came from weight-loss drugs like Ozempic. The 73-year-old reveals she lost about 30 pounds over a year through intermittent fasting alone. Her story highlights natural paths to metabolic health amid GLP-1 hype.
5 min read
Nutrition & Lifestyle Guidance for GLP-1 Medications with Dietician Diana Reid
Following up on real mom experiences with GLP-1 medications, dietician Diana Reid reveals the hidden pitfalls beyond the 'magic wand' hype. From the beach ball metaphor for body set points to essential protein and strength training, learn how to support your body properly. This balanced guide covers benefits like reduced food noise and risks like hair thinning for informed decisions.
5 min read
Novo Nordisk Stock Erases Wegovy Gains After CagriSema Miss
Novo Nordisk's stock has erased the last of its Wegovy-driven gains in a brutal week, down 21% after next-gen obesity drug CagriSema underperformed rivals. Despite 20.2% weight loss in trials, analysts downgrade amid patent cliffs and competition from Eli Lilly's tirzepatide. The company's pivot to oral Wegovy offers hope, but diversification pressures mount.
5 min read
Benefit-Stacking in Bakery: Ardent Mills Targets GLP-1 Demands
GLP-1 medications are reshaping bakery demands, driving growth in high-fiber, high-protein products. Ardent Mills is leading with benefit-stacking strategies using UltraGrain flour and chickpea ingredients to support satiety and digestive health for users. This guide details the research, innovations, and future outlook.
6 min read
IFT on GLP-1 Formulation: Tailoring Functional Foods to Close Nutrition Gaps
As GLP-1 medications surge in popularity, the Institute of Food Technologists (IFT) is guiding brands on functional foods to fill nutrition gaps. From Danone’s Oikos Fusion yogurt to fiber-woven snacks by Lasso, discover how proteins, prebiotics, and micronutrients support satiety and muscle health for users.
5 min read
GLP-1 Drugs May Treat Rare Genetic Obesity, Japanese Study Finds
A new Japanese study reveals that three popular GLP-1 drugs—semaglutide, tirzepatide, and retatrutide—may offer hope for rare genetic obesity linked to MC4R deficiency. In mice models, these drugs led to significant weight loss despite faulty hunger signals. Experts discuss the potential and limitations for human treatment.
5 min read
CagriSema Falls Short vs. Tirzepatide in Obesity Drug Trial
In a pivotal head-to-head trial, Novo Nordisk's next-generation obesity drug CagriSema delivered 23% body weight reduction over 84 weeks, missing the mark against Eli Lilly's tirzepatide at 25.5%. This setback highlights the intense competition in the weight-loss market. Novo shares dropped 11%, while Lilly's rose 4%.
5 min read
US May Fine Hims for Brief Wegovy Compounded Launch
Hims & Hers briefly launched a $49 compounded version of Novo Nordisk's Wegovy, prompting swift FDA backlash and a DOJ referral. Experts say the US could impose fines or injunctions for violating drug laws, though Hims' quick retreat might limit action. This highlights tensions between compounded GLP-1s and approved weight-loss drugs amid surging demand.
5 min read
Can GLP-1 Drugs Power Healthify's Coaching Future? Semaglutide Shift
Healthify, built on coaching, stands at the cusp of transformation as GLP-1 drugs like semaglutide prepare for patent expiry in India by 2026. Deloitte India's Srikanth Mahadevan forecasts 120,000-150,000 incremental patients in diabetes and weight management. This shift could make premium therapies accessible, fueling coaching platforms' growth.
5 min read
Temu Peptides: Why Buying Them Seems Bad
Silicon Valley's biohacking craze has hit Temu, where peptides are sold for pennies, raising alarms about safety and purity. From BPC-157 vials to questionable GLP-1s, these products bypass rigorous testing. A closer look reveals why this mainstream shift could be disastrous for health.
5 min read
Forget Ozempic: Intuitive Surgical Thrives No Matter GLP-1 Winner
Wall Street fixates on GLP-1 giants like Novo Nordisk's Ozempic and Eli Lilly, but Intuitive Surgical continues to thrive with its da Vinci surgical robots. With 11,106 systems installed by end of 2025 and procedures up 18%, this device maker is set for growth regardless of the weight loss drug race. Learn why investors should consider ISRG shares.
5 min read